Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill
By Deidre McPhillips, CNN (CNN) — A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP. In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention
Continue Reading